Screening and Diagnostics

The common application of routine cervical cancer selection has significantly enhanced physicians' skill to detect cancerous and precancerous changes of the cervix. Globally, the human papillomavirus (HPV) has been distinguished in as many as 99.7% of cervical cancer. It is assessed that 50% of women analyzed with invasive cervical cancer have never had a Papanicolaou test, and 10% have not had a Papanicolaou test in the 5 years prior to diagnosis. Sadly, despite widespread screening and treatment of pre-invasive lesions, there are still approximately 12,000 new cases of cervical cancer in the United Kingdom each year and roughly 4,000 annual deaths from the disease. Pregnancy tests are done by detecting human chorionic gonadotropin. The treatment of pregnancy involves a multifaceted approach using 3 main diagnostic tools i.e. history and physical examination, laboratory evaluation, and ultrasonography.

    Related Conference of Screening and Diagnostics

    December 02-03, 2021

    4th World Liver Congress

    Amsterdam, Netherlands
    February 21-22, 2022

    17th Euro-Global Gastroenterology Conference

    Berlin, Germany
    April 25-26, 2022

    International Conference on Hepatitis & Liver diseases

    Sydney, Australia
    June 13-14, 2022

    28th World Conference on Gastroenterology & Hepatology

    Amsterdam, Netherlands
    July 18-19, 2022

    International Conference on Gastroenterology and Liver

    Amsterdam, Netherlands
    July 20-21, 2022

    21th World Gastroenterologists Summit

    Osaka, Japan
    July 20-21, 2022

    Digestive disorders 2022

    Amsterdam, Netherlands
    August 03-04, 2022

    31st World Congress on Nursing

    Rome, Italy
    November 14-15, 2022

    13th International Conference on Liver Diseases & Hepatology

    Amsterdam, Netherlands

    Screening and Diagnostics Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in